Background: Direct measurement of intracellular magnesium using erythrocytes has been suggested as a sensitive indicator for the estimation of body magnesium store. Marked depletion in plasma and erythrocyte magnesium levels was particularly evident in diabetic patients with advanced retinopathy and poor diabetic control. While insulin has been shown to stimulate erythrocyte magnesium uptake, hyperglycemia per se suppressed intracellular magnesium in normal human red cells.
Aim of the study: To investigate the erythrocyte magnesium level in Iraqi type I and II diabetic patients, with specific emphasis on the effect of both, metabolic control and the type of antidiabetic treatments.
Methods: Sixty two diabetic patients (7 with type I and 55 with type II diabetes mellitus) recruited from the outpatient diabetes clinic at the Specialized Center For Endocrine Diseases-Baghdad, during the period from 1st October 2005 to 28th February 2006. Eighteen non-diabetic normomagnesemic healthy controls matched for age and sex were participated in this study. Of the diabetics, 22 were using insulin (7 with type I and 15 with type II diabetes mellitus), 40 were taking oral antidiabetic agents (All with type II diabetes mellitus) and none were using both. Serum and erythrocyte magnesium concentration were measured for both groups, and Glycated hemoglobin levels were estimated only for diabetics.
Results : Mean serum and erythrocyte magnesium levels were significantly (p<0.001) lower in the diabetic group as compared to controls. Serum level of magnesium was not a significant predictor of erythrocyte magnesium concentration. No significant correlation was observed between HbA1c and erythrocyte magnesium. Significantly (p<0.001) lower serum magnesium levels were consistently evident through the entire diabetic subgroups as compared to controls. Erythrocyte magnesium contents were significantly (p<0.001) reduced in patients with type I , type II and type II receiving oral antidiabetic agents, but not in patients with type II receiving insulin (p= 0.120 ), as compared to controls. Significant difference in erythrocyte magnesium levels was observed between patients with type II receiving oral antidiabetic agents and those receiving insulin (p<0.001). The frequency of magnesium deficiency in diabetic patients, as judged by a lower serum magnesium reference limit was constantly 100% in all subgroups. While, judgments based upon a lower erythrocyte magnesium reference limit, discloses variable frequencies in diabetic subgroups.
conclusion: The near normal erythrocyte magnesium levels in type II insulin-receiving patients, could be credited to the stimulatory action of exogenous insulin on cellular magnesium uptake and may indicate a possible role of insulin treatment as a potential implications on health policy, by ameliorating cellular magnesium depletion in the continuously expanding diabetic population.
The formation of Co(II), Ni(II), Cu(II), Zn(II), and Cd(II)-complexes (C1-C5) respectively was studied with new Schiff base ligand [benzyl(2-hydroxy-1-naphthalidene) hydrazine carbodithioate derived from reaction of 2-hydroxy-1-naphthaldehyde and benzyl hydrazine carbodithioate. The suggested structures of the ligand and its complexes have been determined by using C.H.N.S analyzer, thermal analysis, FT-IR, U.V-Visible, 1HNMR, 13CNMR , conductivity measurement , magnetic susceptibility and atomic absorption. According to these studies, the ligand coordinates as a tridentate with metal ions through nitrogen atom of azomethane , oxygen atom of hydroxyl, and sulfur atom of thione
... Show MoreTo investigate the effects of losartan and enalapril on serum uric acid in hypertensive patients with metabolic syndrome, one hundred and twenty six newly diagnosed mild hypertensive patients, having markers of metabolic syndrome included in the study. The patients were divided into two groups. Group 1 (60 patients) was given losartan (50 mg/ day) and group 2 (66 patients) enalapril (20 mg/ day) for a duration of 2 months. A control group of seventy apparently healthy individuals were included. Metabolic syndrome was diagnosed according to diagnostic criteria of metabolic syndrome related to the American National Cholesterol Education Program-Adult Treatment Panel III. Serum uric acid levels were measured bef
... Show More
The study aimed to evaluate the level of MMP‑2 in acute myeloid leukemia (AML) patients in comparison with that in remission status, and healthy subjects, and to find its correlation with hematologic parameters. This study included sixty newly diagnosed AML patients. Remission status was assessed after induction chemotherapy. The overall survival (OS) was determined after 6 months. The plasma MMP‑2 level was measured at diagnosis by enzyme immunoassay. Twenty‑eight healthy individuals were recruited as a control group. Plasma MMP‑2 was higher in AML patients than in healthy individuals (P = 0.005). The level of MMP‑2 was much higher in the M5 subtype than in the other subtypes (P = 0.0001). There was no statistically significant d
... Show More
(2)
(8)
(8)
The new tridentate Schiff base ligand (HL)namely 2-{[1-(3-amino-phenyl)-ethylidene]-hydrazono methyl}- phenol containing (N N O)as donors atoms was prepared in two steps:Step (1): By the reaction of 3- aminoacetophenone with hydrazine monohydrate under reflux in methanol and drops of glacial acetic acid gave the intermediate compound 3-(1- hydrazono ethyl)-phenol amine.Step (2): By the reaction of 3-(1-hydrazono ethyl)-phenol amine with salicyaldehyde under reflux in methanol, gave the ligand (HL).The prepared ligand was characterized by I.R, U.V-Vis,1H- 13C NMR spectra and melting point and reacted with some metal ions under reflux in methanol with (1:1) ratio gave complexes of the general formula: [MClL]. Where: M= Mn(II), Fe(II), Co(II),
... Show MorePeripheral artery disease (PAD) is associated with increased oxidative stress and impaired endothelial function. Ticagrelor treatment improves antioxidant properties in addition to its antiplatelet effects. This study investigated the impact of Ticagrelor treatment on serum superoxide dismutase (SOD) levels and other biochemical parameters in PAD patients. It also evaluated the potential diagnostic accuracy and clinical utility of specific biomarkers based on receiver operating characteristic (ROC) analysis. Seventy individuals were categorized into healthy control (n=40), baseline PAD patients not on Ticagrelor (B-PAD, n=30), and same PAD patients after treated with Ticagrelor (A-PAD, n=30). Parameters measured included SOD concent
... Show More